Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zhenbin, Chen, Zihao, Zhang, Chao, Zhong, Wenzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706908/
https://www.ncbi.nlm.nih.gov/pubmed/31463163
http://dx.doi.org/10.1186/s40164-019-0143-z
_version_ 1783445775144976384
author Qiu, Zhenbin
Chen, Zihao
Zhang, Chao
Zhong, Wenzhao
author_facet Qiu, Zhenbin
Chen, Zihao
Zhang, Chao
Zhong, Wenzhao
author_sort Qiu, Zhenbin
collection PubMed
description Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits for wild-type advanced NSCLC patients with acceptable adverse effects. Though beneficiary population is limited from monotherapy, combination strategies are expanding indicators. Retrospective evidences suggested ICIs are also potentially useful for brain metastasis. Furthermore, the combination of ICIs and surgery are to prolong progression free survival time for local advanced patients. Additionally, novel agents targeting in immune checkpoints other than PD-1/L1 demonstrated potential values in anticancer immunity. Herein, we summarize the novel therapies of checkpoint inhibitors in NSCLC treatment and some other potential immunotherapy to provide a conspectus for novel immunotherapy in NSCLC and perspective for the future in anti-cancer treatment.
format Online
Article
Text
id pubmed-6706908
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67069082019-08-28 Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer Qiu, Zhenbin Chen, Zihao Zhang, Chao Zhong, Wenzhao Exp Hematol Oncol Review Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits for wild-type advanced NSCLC patients with acceptable adverse effects. Though beneficiary population is limited from monotherapy, combination strategies are expanding indicators. Retrospective evidences suggested ICIs are also potentially useful for brain metastasis. Furthermore, the combination of ICIs and surgery are to prolong progression free survival time for local advanced patients. Additionally, novel agents targeting in immune checkpoints other than PD-1/L1 demonstrated potential values in anticancer immunity. Herein, we summarize the novel therapies of checkpoint inhibitors in NSCLC treatment and some other potential immunotherapy to provide a conspectus for novel immunotherapy in NSCLC and perspective for the future in anti-cancer treatment. BioMed Central 2019-08-22 /pmc/articles/PMC6706908/ /pubmed/31463163 http://dx.doi.org/10.1186/s40164-019-0143-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Qiu, Zhenbin
Chen, Zihao
Zhang, Chao
Zhong, Wenzhao
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title_full Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title_fullStr Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title_full_unstemmed Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title_short Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
title_sort achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706908/
https://www.ncbi.nlm.nih.gov/pubmed/31463163
http://dx.doi.org/10.1186/s40164-019-0143-z
work_keys_str_mv AT qiuzhenbin achievementsandfuturesofimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT chenzihao achievementsandfuturesofimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT zhangchao achievementsandfuturesofimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT zhongwenzhao achievementsandfuturesofimmunecheckpointinhibitorsinnonsmallcelllungcancer

Ejemplares similares